Approaches for Overcoming Obstacles to Successful Implementation in the Clinic Biomarkers have become some of the most desired clinical and research tools in the life sciences. They have the potential ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio") announced a strategic ...

One of the earliest examples of a vaccine biomarker assay still in use is the polio antibody neutralization assay, which evaluates the immunogenicity of different polio vaccines. This assay is used to ...

FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...

Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis; Weill Cornell Medicine-Qatar (WCM-Q); and The Michael J. Fox Foundation for Parkinson’s Research ...

Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers Simplifies biomarker assay development and ...

Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research projects ...

Companion diagnostics (CDx) are vital to precision oncology, enabling clinicians to match patients with therapies based on personalized factors such as biomarker profiles. However, traditional CDx ...

ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a leader in ultra-sensitive immunoassay technologies, ...